Primary-source record

MaterialTrial registry change

Olema Oncology: on track for palazestrant OPERA-01 Phase 3 topline in Q1 2027

This quarterly update restates that the pivotal Phase 3 OPERA-01 trial of palazestrant remains on track to report top-line data in Q1 2027. It also notes continued strong enrollment in the pivotal Phase 3 OPERA-02 trial of palazestrant plus ribociclib.

Key facts

Filed
Sep 30, 2026, 12:00 PM
Event
Trial registry change
Direction
Neutral
Company
OLMAOlema
Source
SEC 8-K
Confidence
Sourced

Source excerpt

EX-99.1 2 olma-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Olema Oncology Reports Third Quarter 2026 Financial and Operating Results • On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027 • Continued strong enrollment in the pivotal Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136 • Appointed Jason O’Byrne, MBA, as Chief Financial Officer • Ended the third quarter with $413.8 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, November 10, 2026 (Globe NewsWire) – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2026. “As we approach top-line data from our pivotal Phase 3 OPERA-01 trial in the first quarter of 2027, we remain confident in palazestrant’s potential to emerge as a differentiated endocrine therapy in second- and third-line metastatic breast cancer,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “Turning to our pivotal Phase 3 OPERA-02 trial in first-line metastatic breast cancer, momentum continues to build. Enrollment is accelerating, investigator interest is strong, and patients with frontline disease continue to require better therapeutic options. We believe that pa

SEC 8-K

More on this asset

Nov 20, 2026
03:25 PM
OLMAOlema

palazestrant · NCT07085767 registry update

Trial registry changeClinicalTrials.gov
Sep 23, 2026
03:23 PM
OLMAOlema

palazestrant · NCT07085767 registry update

Trial registry changeClinicalTrials.gov
Jan 12, 2026
09:44 PM
OLMAOlema

Olema updates OPERA-01/02 Phase 3 timelines for palazestrant

Trial registry changeSEC 8-K
Oct 20, 2025
09:13 PM
OLMAOlema

Olema presents palazestrant + ribociclib Phase 1b/2 data at ESMO 2025

Conference presentationSEC 8-K
Olema Oncology: on track for palazestrant OPERA-01 Phase 3 topline in Q1 2027 | SimianX AI